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Abstract
Olfactory deficits have been reported in major depressive disorder (MDD). However, it 
remains largely unknown whether MDD is associated with abnormalities in olfactory 
sulcus morphology, a potential marker of olfactory system development. This magnetic 
resonance imaging study investigated the length and depth of the olfactory sulcus in 29 
currently depressed patients, 27 remitted depressed patients, and 33 age- and gender-
matched healthy control subjects. Both current and remitted MDD patients had 
significantly shallower olfactory sulci bilaterally as compared with controls. Only for 
male subjects, the right olfactory sulcus was significantly shorter in remitted MDD 
patients than in controls. The right sulcus depth was negatively correlated with number 
of depressive episodes in the entire MDD group and with residual depressive symptoms
in the remitted MDD group. Medication status, presence of melancholia, and 
comorbidity with anxiety disorders did not affect the sulcus morphology. These 
findings suggest that abnormality of the olfactory sulcus morphology, especially its 
depth, may be a trait-related marker of vulnerability to major depression. 
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1. Introduction
Several lines of evidence have suggested that olfactory function is involved in 
emotional regulation, with common underlying neural substrates (Soudry et al., 2011; 
Takahashi et al., 2015). Although not consistently, patients with major depressive 
disorder (MDD) have been reported to have olfactory deficits, especially for olfactory 
sensitivity (reviewed by Burón and Bulbena, 2013; Schablitzky and Pause, 2014), 
which are associated with the severity of depressive symptoms and at least partly 
persist even after the clinical improvement (Naudin et al., 2012). These previous 
findings implicate a role for the olfactory system in the pathogenesis of depression 
(Yuan and Slotnick, 2014).
The olfactory sulcus appears during fetal development at around 16 weeks of 
gestation (Chi et al., 1977) and its depth has been related to olfactory function in 
healthy subjects (Hummel et al., 2003). Regarding psychiatric disorders, an abnormally 
shallow olfactory sulcus has been reported in schizophrenia (Takahashi et al., 2013; 
Turetsky et al., 2009), supporting the notion that olfactory dysfunction may represent a 
marker of early neurodevelopmental abnormalities related to vulnerability to psychosis 
(Brewer et al. 2001, 2003; Kamath et al., 2014). On the other hand, several magnetic 
resonance imaging (MRI) studies in MDD have provided evidence for trait- and 
vulnerability-related alterations in volume (Lorenzetti et al., 2009 b, 2010; Opel et al., 
2016; Takahashi et al., 2010) or surface morphology (Peng et al., 2015) of limbic and 
cortical structures, suggesting neurodevelopmental pathology in depressive disorders 
(Ansorge et al., 2007). Interestingly, Zhang et al. (2009) found decreased cortical 
gyrification in MDD, which may reflect neural underdevelopment during gestation, 
predominantly in the olfactory system structures (i.e., cingulate, insula, and 
orbitofrontal regions). However, it remains largely unknown whether MDD patients 
exhibit morphologic changes of the olfactory sulcus.
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This MRI study investigated the length and depth of the olfactory sulcus in 
current depressed patients (cMDD), individuals with a history of major depression but 
who are currently in remission (rMDD), and healthy comparison subjects. This 
approach enabled us to examine whether abnormalities of the olfactory sulcus in MDD, 
if present, reflect state or trait markers of the disorder. On the basis of enduring 
olfactory deficits in MDD patients observed during episodes and after remission 
(Naudin et al., 2012), as well as the potential role of olfactory sulcus depth as a 
neurodevelopmental marker, we predicted that both cMDD and rMDD patients would 
have shallower olfactory sulci compared with controls, representing a trait-related 
feature of MDD. We also examined the influence of severity of depressive symptoms 
and subtypes of depression (e.g., co-morbid anxiety disorder, melancholic versus non-
melancholic) on olfactory sulcus morphology in the MDD patients.
2. Methods 
2.1. Subjects
Eighty-nine subjects were recruited in the study, of which 29 received a current 
diagnosis of major depressive disorder (cMDD), 27 were currently medically and 
psychiatrically well individuals with a previous history of major depressive disorder 
(rMDD), and 33 were healthy controls (Table 1). Seven rMDD patients had a total Beck
Depression Inventory (BDI; Beck and Steer, 1987) score > 18, but did not fulfill the 
criteria of MDD by the Structured Clinical Interview for DSM-IV (SCID-IV-TR; First 
et al., 2001). Demographic and clinical characteristics of the same MDD subjects, 
recruited through advertisement in the local media from the general community and via 
outpatient mental health clinics, have been described previously (Lorenzetti et al., 
2009a). The relevant Human Research Ethics Review committees approved the study 
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protocol, and participants gave written informed consent after a complete description of
the study.
Participant inclusion criteria were: age 18-50 years, English as a preferred 
language, and current IQ > 70. Exclusion criteria were: a history of significant head 
injury, seizures, impaired thyroid function and steroid use, neurological diseases, 
electroconvulsive therapy within the past 6 months, and gross brain abnormalities. All 
the depressed subjects with another current Axis I psychiatric disorder (other than 
anxiety disorders) were excluded, as well as any healthy controls who had a personal 
history of psychiatric illness, drug or alcohol dependence.
All participants underwent a clinical and neuropsychological assessment by 
experienced research psychologists at Orygen Youth Health, Melbourne. Participants 
were assessed with the SCID-IV-TR, the BDI, the Mood and Anxiety Symptom 
Questionnaire (MASQ; Watson et al., 1995), Positive Affect and Negative Affect Scale 
(PANAS; Watson et al., 1988), and the Alcohol Use Disorders Identification Test 
(AUDIT; Babor et al., 1992). Measures of premorbid and current intelligence were 
obtained using the Wechsler Test of Adult Reading (Wechsler, 2001) and the Wechsler 
Abbreviated Scale of Intelligence (Wechsler, 1999). 
Medication use in the preceding 6 months was also assessed. Thirty-three (21 
cMDD and 12 rMDD) patients were on a stable medication regimen for at least 6 
months preceding the scan. Of these, seventeen patients were on selective serotonin 
reuptake inhibitors, four on venlafaxine, three on mirtazapine, two each tricyclics and 
monoamine-oxidase inhibitors, and one each on lithium and reboxetine. Three patients 
were receiving combination therapy (paroxetine and benzodiazepine; escitolopram and 
mirtazapine; and lithium and dothiepin), while 3 cMDD and 6 rMDD patients were 
medication-naïve.
2.2. Magnetic resonance imaging procedures 
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MRI scans were acquired with a 1.5-T Magnetom Avanto scanner (Siemens 
Medical System, Inc., Erlangen, Germany) at the St. Vincent’s Hospital Melbourne, 
Victoria. Structural 3D T1-weighted images were obtained with the following 
parameters: time to echo = 2.3 ms, time repetition = 2.1 ms, flip angle = 15°, matrix 
size = 256 x 256, voxel dimension = 1 x 1 x 1 mm. Additionally, MRI abnormalities 
were assessed using a high-resolution T2-weighted scan. The intracranial volume (ICV)
was estimated from manual tracing on a sagittal reformat of the original T1-weighted 
images as previously described (Eritaia et al., 2000); the groups did not significantly 
differ in their ICVs (Table 1).
    For the assessment of the olfactory sulcus, the images were processed on a Linux PC 
using Dr. View software (AJS, Tokyo, Japan). Brain images were realigned in three 
dimensions and reconstructed into contiguous coronal images with a 1-mm thickness, 
perpendicular to the anterior commissure-posterior commissure line. As described in 
detail elsewhere (Takahashi et al., 2013), one rater (TT), who was blind to the subjects’ 
identity, measured the depth of the olfactory sulcus in all 1-mm coronal slices where the
sulcus could be identified (Fig. 1). On each coronal slice, the olfactory sulcus was 
traced beginning with the deepest point of the sulcus and ending inferiorly with a 
tangent line connecting the top surfaces of the gyrus rectus and medial orbital gyrus 
(Rombaux et al., 2009). While previous studies measured the sulcus depth by drawing a
straight line on one coronal slice (Huart et al., 2011; Rombaux et al., 2009), we traced 
the surface of the intrasulcal gray matter on entire coronal slices containing the sulcus 
(approximately 40-50 slices) in order to reflect the contour of the sulcus into the 
measurement. The length of the sulcus in the anterior-posterior direction (mm) was 
equal to the number of these coronal slices. The average depth of the sulcus on each 
hemisphere was calculated as follows: sum of the depth in all slices containing the 
sulcus / slice number [i.e., sulcus length (mm)]. Intra- and inter-rater (TT and DS) 
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intraclass correlation coefficients (ICCs) for the length and depth of the olfactory sulcus
in a reliability data set of 10 randomly selected brains were over 0.90.
2.3. Statistical analysis
Clinical and demographic differences between groups were examined with one-
way analysis of variance (ANOVA) or chi-square test.
The average depth and length of each olfactory sulcus were analyzed using the 
repeated measures analysis of covariance (ANCOVA), with age and ICV as covariates, 
diagnosis and gender as between-subject factors, and hemisphere as a within-subject 
variable. Post hoc Scheffé tests were used to follow up the significant main effects or 
interactions yielded by these analyses.
The relationships between the olfactory sulcus measures and clinical variables 
were examined using Spearman’s rank correlation coefficients because of a skewed 
distribution of clinical variables. The association of premorbid or current IQ 
(adequately normally distributed according to the Kolmogorov-Smirnov test) to the 
sulcus measures was examined using Pearson’s partial correlation coefficients 
controlling for age and ICV. The volumes of the amygdala (Lorenzetti et al., 2010) and 
insula (Takahashi et al., 2010) were available for the subjects in this study; relationships
between the olfactory sulcus measures and these volumetric data were also examined 
for each hemisphere using Pearson’s partial correlation coefficients controlling for age 
and ICV. Statistical significance was defined as p < 0.05; Bonferroni correction was 
applied to the correlational analyses.
3. Results
3.1. Demographic and clinical data
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Comparison of the groups revealed no significant differences in age, gender, and
intelligence but, as expected, measures of depressive and anxiety symptoms were 
significantly different between groups (Table 1). The cMDD patients, as compared to 
rMDD patients, had an earlier age of onset, a higher proportion of participants on 
medication in the previous 6 months, and a higher rate of co-morbid anxiety disorder.
3.2. Depth and length of the olfactory sulcus
ANCOVA and post-hoc analyses showed that both cMDD and rMDD patients 
had significantly shallower olfactory sulci bilaterally as compared with healthy 
controls, but there was no difference between the two MDD groups (Table 2, Fig. 2). 
ANCOVA revealed a significant group by hemisphere by sex effect for olfactory sulcus 
length. Post-hoc analyses revealed that the right olfactory sulcus was significantly 
shorter in rMDD patients than in controls only for males (Table 2).
Dividing the patient group into those who were (n = 33) and those who were not
(n = 19) taking medication in the preceding 6 months revealed no effect of medication 
status on the sulcus morphology [depth, F (1, 48) = 0. 31, p = 0.579; length, F (1, 48) = 
2. 36, p = 0.131]. There were no differences in sulcus morphology when melancholic (n
=10) and non-melancholic (n = 18) subgroups of cMDD patients [depth, F (1, 24) = 
0.04, p = 0.845; length, F (1, 24) = 0.45, p = 0.508] or depressed patients with (n = 22) 
and without (n = 33) co-morbid anxiety disorder [depth, F (1, 51) = 0.26, p = 0.614; 
length, F (1, 51) = 0.07, p = 0.787] were compared.
3.3. Correlational analysis
Age and IQ (current, premorbid) did not correlate with the sulcus measures in 
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controls, the depression group as a whole, or the cMDD and rMDD subgroups. The 
right sulcus depth was negatively correlated with number of depressive episodes in the 
depressed patients as a whole (rho = -0.395, p = 0.012) and with MASQ scale reflecting
general depression in the rMDD patients (rho = -0.588, p = 0.002). No significant 
correlations were found between the sulcus measures and other clinical variables (onset 
age, illness duration, total BDI score, PANAS subscale scores, and AUDIT score) after 
Bonferroni correction for multiple comparisons.
There was no significant relationship between the olfactory sulcus measures, 
amygdala volume, and insular cortex volume in the controls, the depression group as a 
whole, or the cMDD and rMDD subgroups. 
4. Discussion
To our knowledge, this is the first MRI study to report morphologic changes of 
the olfactory sulcus in MDD patients. In this study, both current and remitted MDD 
patients had significantly shallower olfactory sulci as compared with healthy controls. 
The right sulcus depth was negatively correlated with number of depressive episodes in 
the depressed patients, which may reflect vulnerability to relapse, and with degree of 
residual depressive symptoms in the remitted patients. These findings suggest that 
abnormality of the olfactory sulcus morphology may represent a trait-related marker of 
vulnerability to major depression.
Depressed patients principally exhibit reduced olfactory sensitivity and deficits 
in the hedonic responses to olfactory stimuli, which are correlated with the severity of 
depressive symptoms (Atanasova et al., 2008; Yuan and Slotnick, 2014) but also partly 
persist even after remission (Naudin et al., 2012; Pause et al., 2001), and are probably 
not mediated by antidepressant treatment (Schablitzky and Pause, 2014). These 
olfactory findings, which may represent both state and trait abnormalities, might be 
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partly attributable to common underlying neural substrates for olfactory and emotional 
processing (i.e., limbic structures such as amygdala, insula, cingulate, and orbitofrontal 
cortex; Soudry et al., 2011). Indeed, increasing neuroimaging evidence has 
demonstrated morphologic and functional abnormalities of these olfactory system 
structures in MDD (reviewed by Atanasova et al., 2008; Lorenzetti et al., 2009b). The 
present MRI findings of abnormally shallow olfactory sulcus in MDD may also support
these olfactory ability findings, as this anatomical abnormality could be associated with
embryonic disruption of olfactory system development (Abolmaali et al., 2002; 
Hummel et al., 2003). These olfactory and neuroimaging findings may implicate the 
role of impaired olfactory system, which has a close relation with emotional regulation, 
in the pathophysiology of major depression.
In this study, not only currently but also remitted depressed patients, who were 
psychiatrically well but potentially vulnerable to illness relapse, showed significantly 
shallower olfactory sulcus as compared with healthy subjects. We also found shorter 
right sulcus only in male remitted patients, but this could not be generalized because of 
very small number of male remitted patients (n = 9). The olfactory sulcus morphology, 
which is thought to be stable at least during the period of adolescence to midlife 
(Takahashi et al., 2013), did not correlate with age or illness duration in this study. 
Given that olfactory sulci on the human brain appear at 16 weeks gestation and are 
prominent at 25 weeks (Chi et al., 1977), our findings may partly support the 
hypothesis by Ansorge et al. (2007) that neurodevelopmental factors affect the 
maturation of brain circuits involved in emotional function to increase diathesis to 
depressive disorder later in life. The olfactory sulcus depth did not correlate with 
symptom severity during depressive episodes, but our results suggested its association 
with vulnerability to relapse and residual depressive symptoms after clinical remission. 
In combination with the finding of enduring olfactory deficits in remitted MDD patients
(Naudin et al., 2012) as well as MRI findings that altered surface morphology (e.g., 
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gyrification), which probably reflects neural underdevelopment during gestation, 
predominantly in olfactory system structures (i.e., cingulate, insula, and orbitofrontal 
regions) in MDD (Peng et al., 2015; Zhang et al., 2009), our findings may provide 
support for the notion that abnormalities in olfactory system development during 
gestation and consequent olfactory deficits are at least partly reflect trait-related 
vulnerability factors. However, evaluation of whether olfactory sulcus morphology is a 
true trait marker of vulnerability to depression versus an enduring ‘scar’ of depressive 
episodes will require a future study in the subjects of various illness stages ideally 
including the vulnerable individuals prior to the onset of their first depressive episode.
Regarding other olfactory structures in the present MDD cohort, we have 
previously reported reduced insular cortex volume in both rMDD and cMDD groups 
(Takahashi et al., 2010) and increased amygdala volume only in the rMDD group 
(Lorenzetti et al., 2010). It is possible that abnormalities in one area in the olfactory 
circuits could cause secondary functional/structural alterations in other regions 　
(Depciuch et al., 2015; Yuan and Slotnick, 2014). However, we found no direct relation 
between olfactory sulcus morphology and volumes of these olfactory structures, 
suggesting that distinct brain regions might be differentially involved in the 
neurobiology of MDD even within the olfactory circuits. These results may be partly 
consistent with recent functional MRI finding of imbalanced brain activity within the 
olfactory circuits in MDD patients (Zhang et al., 2016). On the other hand, brain 
morphology could change during the course of depression (Soriano-Mas et al., 2011), 
possibly reflecting stress-toxicity (Duman, 2002), neurohumoral changes (e.g., 
hypothalamic-pituitary-adrenal axis dysregulation; Lorenzetti et al., 2009a), and/or 
neuroplastic effects of medication (Frodl et al., 2008; Moore et al., 2000). Thus, further 
neuroimaging studies using longitudinal designs will be needed to clarify the 
characteristics of structural/functional abnormalities in the olfactory circuits during the 
course of major depression.
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A few possible confounding factors may have affected our findings. First, we 
did not assess olfactory function or additional olfactory structures (e.g., olfactory bulb), 
representing a limitation of the study. Second, complete lifetime medication data of the 
patients were not available. However, no difference in sulcus morphology was found 
between patients who were and were not on antidepressant medication in the preceding 
six-month period. Third, in addition to a relatively small sample size especially for male
subjects, potential heterogeneity between the MDD subgroups (e.g., earlier onset, lower
current IQ, and higher prevalence of co-morbid anxiety disorders in the cMDD 
patients) might have biased our results. However, all of these potential confounding 
factors did not relate to sulcus morphology of the MDD patients in this study. Finally, 
given that the olfactory sulcus abnormalities are also reported in other psychiatric 
disorders such as schizophrenia (e.g., Takahashi et al., 2013) and reduced global 
sulcation appears to be a feature of major depression (Penttilä et al., 2009), the disease 
and regional specificities of our findings should be further tested.
In conclusion, the present study indicates that patients with unipolar depression 
have an abnormality of the olfactory sulcus morphology (especially its depth), which is 
also evident in remitted depressed subjects who are in a vulnerable clinical state. These 
findings are unlikely to be due to the effects of medication or co-morbid anxiety 
disorder, suggesting that the olfactory sulcus morphology may be a trait-related 
vulnerability marker of MDD. Further studies of both neuroimaging and olfactory 
ability assessments will be needed to examine possible role of the olfactory system, 
which has a close relation with emotional regulation (Soudry et al., 2011), in the 
pathophysiology of major depression.
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Figure Legends
Fig. 1. Olfactory sulci on coronal (A) and axial (B) views, which were colored on 1-mm
consecutive coronal slices. Panel A and the dotted line on panel B show the plane of the
posterior tangent through the eyeballs (PPTE). 
Fig. 2. Scatter plots of olfactory sulcus depth in healthy controls, currently depressed 
patients (cMDD), and remitted depressed patients (rMDD). Horizontal bars indicate 
means of each group. *p < 0.01. 
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